abstract |
This invention relates to crystalline forms of [4-carbamoyl-1- (3-fluorobenzyl) -2,7-dihydroxy-7-methyl-octyl] -amide of quinoxaline-2-carboxylic acid, useful in the treatment or prevention of a disorder or condition through CCR1 receptor antagonization, and its methods of preparation and use. |